UK's FTSE 100 rises on healthcare, energy boost; set for firm weekly gains

By Reuters News

- Britain's FTSE 100 .FTSE rose on Friday, with healthcare and energy-related companies providing the biggest boosts, keeping the blue-chip index on track for its best weekly showing in about a month.

The index gained 0.3% to 10,891.1 points by 1104 GMT, while the midcap FTSE 250 .FTMC slipped 0.3%.

  • Both benchmarks, however, were headed for firm weekly gains, with the FTSE 100 set for its best week since mid-October

  • Aviva AV.L rose 2.7% to lead FTSE 100 gainers after posting a 19% rise in general insurance premiums for the first nine months of 2026

  • Oil majors BP BP.L and Shell SHEL.L gained about 1% each and were among the biggest boosts to the index

  • Healthcare heavyweights AstraZeneca AZN.L and GSK GSK.L also nudged higher, offering support to the main index

  • Precious metal miners .FTNMX551030 extended losses from the previous session, slipping 0.6% and set for an over 6% fall for the week, tracking recent weakness in gold prices

  • Aerospace and defence-related stocks were among the losers, with Rolls-Royce RR.L, Weir Group WEIR.L and Babcock International BAB.L down between 0.9% and 1.6%

  • DFS Furniture DFSD.L dropped 4.5% after the sofa retailer warned that the upholstery market had softened further, hit by strained household finances and weaker consumer confidence

  • Investors will look out for a US producer prices reading due later in the day for clues on the Federal Reserve's interest rate path

  • The domestic data calendar is packed next week, with inflation readings and a jobs report expected

  • After the Bank of England increased its main lending rate earlier this month, traders are pricing in an over 82% chance of another 25-basis-point hike next month, according to data compiled by LSEG

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.